ABBV
The headline: a beat with some extra sparkle
AbbVie came in with a quarter that looked pretty solid on paper — adjusted EPS of $2.71 versus $2.65 expected, and revenue of $16.62 billion, up 10% year over year. The stock liked that, trading higher as investors got a fresh reminder that the company still knows how to throw off cash without making a spectacle of it.
Why the Street cared
This wasn’t just a numbers-only victory lap. AbbVie also nudged investors with FY2026 EPS guidance of $14.37 to $14.57, which gives the market a cleaner runway to model the next few quarters. In plain English: when a big pharma name beats, raises, and keeps the dividend conveyor belt humming, people tend to stop doom-scrolling and start recalculating fair value.
Pipeline and deal drama, but make it pharma
The other spark came from the growth story. AbbVie got a boost from late-breaking Phase 2 data for Elahere (mirvetuximab), which showed encouraging efficacy and safety in platinum-sensitive ovarian cancer. On top of that, it struck an exclusive global licensing deal with Haisco for pain assets, reportedly worth around $715 million to $745 million. Translation: AbbVie is still shopping for tomorrow’s revenue instead of relying on yesterday’s blockbuster cash machine.
The investor takeaway
Wall Street also had the usual chorus of optimism, with multiple firms bumping price targets higher. That doesn’t guarantee the stock keeps climbing, but it does help set the tone: AbbVie looks like a classic big-cap pharma story where the dividend, pipeline, and valuation all wrestle for attention at the same dinner table.
Big picture: AbbVie is trying to sell investors a pretty familiar pitch — dependable income today, a pipeline of maybe-meaningful tomorrow, and just enough growth to keep the story from going stale.